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Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is an important foodborne
pathogen causing severe diseases in humans worldwide. Currently, there is no
specific treatment available for EHEC infection and the use of conventional antibiotics
is contraindicated. Therefore, identification of potential therapeutic targets and
development of effective measures to control and treat EHEC infection are needed.
Lipopolysaccharides (LPS) are surface glycolipids found on the outer membrane
of gram-negative bacteria, including EHEC, and LPS biosynthesis has long been
considered as potential anti-bacterial target. Here, we demonstrated that the EHEC
rfaD gene that functions in the biosynthesis of the LPS inner core is required for the
intestinal colonization and pathogenesis of EHEC in vivo. Disruption of the EHEC rfaD
confers attenuated toxicity in Caenorhabditis elegans and less bacterial colonization in
the intestine of C. elegans and mouse. Moreover, rfaD is also involved in the control of
susceptibility of EHEC to antimicrobial peptides and host intestinal immunity. It is worth
noting that rfaDmutation did not interfere with the growth kinetics when compared to the
wild-type EHEC cells. Taken together, we demonstrated that mutations of the EHEC rfaD
confer hypersusceptibility to host intestinal innate immunity in vivo, and suggested that
targeting the RfaD or the core LPS synthesis pathway may provide alternative therapeutic
regimens for EHEC infection.
Keywords: enterohemorrhagic Escherichia coli (EHEC), RfaD/GmhD/WaaD, lipopolysaccharide (LPS),
antimicrobial peptides (AMPs), intestinal innate immunity, Caenorhabditis elegans
Kuo et al. EHEC and Host Intestinal Immunity
INTRODUCTION
Enterohemorrhagic Escherichia coli (EHEC), themost recognized
serotype of which is O157:H7, is a gram-negative foodborne
pathogen which can cause diarrhea and other severe symptoms,
like hemorrhagic colitis (HC), hemolytic-uremic syndrome
(HUS) and acute renal failure in humans (Pennington, 2010).
However, treatment of EHEC infection with antibiotics is not
recommended because more EHEC virulence factors, such as
Shiga toxins and endotoxins, may be released and exacerbate
severe syndromes in patients (Pacheco and Sperandio, 2012;
Freedman et al., 2016). Currently, only palliative care can be
applied after EHEC infection. Therefore, the development of a
novel therapeutic strategy for EHEC infection is urgently needed.
Several virulence factors expressed by EHEC contribute to its
pathogenicity (Nguyen and Sperandio, 2012). The Shiga toxins
(Stxs) produced by EHEC are responsible for HUS and HC.
The type III secretion system (T3SS) and effectors encoded
by the locus of enterocyte effacement (LEE) pathogenicity
island are required for formation of the attaching and effacing
(A/E) lesions on host intestinal epithelium. Although many
virulence factors and mechanisms of EHEC have been reported,
therapeutic strategies targeting these specific virulence factors
remain under investigation (Nguyen and Sperandio, 2012;
Pacheco and Sperandio, 2012).
Lipopolysaccharides (LPS) are surface phosphorylated
lipoglycans on the outer leaflet of the outer membrane in gram-
negative bacteria (Raetz and Whitfield, 2002), including EHEC.
E. coli LPS is a complex molecule that can be divided structurally
into three parts (Figure 1A), lipid A, core oligosaccharides,
and O-antigen polysaccharide chains (Raetz and Whitfield,
2002). The core oligosaccharide can be further divided into
the inner and outer cores respectively. The inner core is
composed of 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo)
and ADP-heptose residues, and the outer core provides
the attachment site for the O-polysaccharide chain and is
constructed of hexoses and 2-acetoamido-2-deoxy-hexoses.
ADP-heptose is a crucial component of the LPS inner core,
and it connects the outer part of LPS to Kdo between the
Kdo2-lipid A and O-antigen. Moreover, ADP-heptose is
also required to maintain outer membrane integrity, restrict
permeability and prevent attack by the complement system
(Raetz and Whitfield, 2002; Chang et al., 2011). The E. coli
chromosomal rfa, also known as gmh or waa, operons encode
enzymes needed for the stepwise assembly of the major core
oligosaccharides (Raetz and Whitfield, 2002). The biosynthetic
pathway for the nucleotide-activated glycero-manno-heptose
precursors of LPS has been characterized in E. coli (Figure 1B).
It contains five catalytic steps that are required for generation
of ADP-L-glycero-D-manno-heptose, a molecule essential
for the first heptose and can be transferred to Kdo (Valvano
et al., 2002). The rfaD gene, also named gmhD or waaD,
encodes the ADP-L-glycero-D-manno-heptose-6-epimerase
which catalyzes the conversion of ADP-D-glycero-D-manno-
heptose to ADP-L-glycero-D-manno-heptose, the last step in
the ADP-L-glycero-D- manno-heptose synthetic pathway. The
biochemistry of this biosynthetic pathway in E. coli has long
been characterized; however, targeting RfaD and the core LPS
biosynthesis enzymes for the treatment of EHEC infection
remains largely unexplored.
Many animal models have been developed to facilitate the
study of EHEC pathogenesis. Such models have been used to
explore differences in relative toxicity among different types of
Stxs (Tesh et al., 1993), assess the protective capacity of novel
therapeutic methods (Sheoran et al., 2005; Armstrong et al.,
2006; Bentancor et al., 2009), and model the pathogenesis of
HUS (Sauter et al., 2008). Here, we utilized the model organism
Caenorhabditis elegans, which might encounter EHEC in its
natural habitat, as a surrogate host to study EHEC infection
(Kenney et al., 2005; Anderson et al., 2006; Chou et al., 2013).
Several characteristics of C. elegans make it suitable for studying
pathogen and host interactions, including its small size, rapid life
cycle, ease of conducting forward, reverse and chemical genetic
screens, and sharing of conserved innate immune pathways
with humans (Irazoqui et al., 2010), which are invaluable
for investigating infection. Of particular relevance, C. elegans
intestinal cells share similar anatomic features with humans
(McGhee, 2007), which makes it an attractive model for the study
of intestinal pathogens, including EHEC. We have demonstrated
that EHEC can colonize and induce characteristic A/E lesions in
the intestine ofC. elegans, and Shiga toxin 1 (Stx1) is also required
for the full virulence of EHEC pathogenicity in C. elegans
(Chou et al., 2013). All these facts suggest that EHEC exerts
similar and conserved virulence mechanisms in C. elegans and
humans.
Herein, we report that inactivation of the EHEC RfaD and
other core LPS biosynthesis enzymes attenuated its toxicity
to C. elegans. Moreover, deletion of the EHEC rfaD gene
significantly reduced its intestinal colonization in animal hosts,
including C. elegans and mouse in vivo, and increased its
susceptibility to several antimicrobial peptides (AMPs) in vitro.
Our results highlight the importance of RfaD and core LPS in
host intestinal colonization and suggest targeting RfaD or the
core LPS synthesis pathway in EHEC may provide as potential
therapeutic strategies for EHEC infection.
MATERIALS AND METHODS
Bacterial and C. elegans Strains
The bacterial strains and plasmids used for this study are
listed in Tables S1, S2 respectively. The enterohemorrhagic
E. coli O157:H7 clinical isolates, EDL933 and HER1266, were
from the Bioresource Collection and Research Center (BCRC,
Taiwan). The EHEC mutants were generated by the lambda
Red recombinase system (Datsenko and Wanner, 2000) and
described in the Supplementary Information. All EHE-related
biohazardous wastes were disinfected and disposed according
to the Biosafety Level 2 (BSL-2) regulation. The Bristol N2
is the wild-type Caenorhabditis elegans strain. The DA597
strain contains two mutations in the phm-2(ad597) allele and
results in abnormal function of the pharynx (Avery, 1993). The
GK454 strain with the mCherry::ACT-5 transgene was used
to monitor the microvillar actin rearrangement (Sato et al.,
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2 August 2016 | Volume 6 | Article 82
Kuo et al. EHEC and Host Intestinal Immunity
FIGURE 1 | Lipopolysaccharide (LPS) structure and the core-lipid A biosynthetic pathway. (A) A graphic representation of the LPS structure of E. coli. LPS
contains several conserved components: lipid A, inner core, outer core and O-antigen (Raetz and Whitfield, 2002). (B) Pathways for the biosynthesis of the LPS core
lipid A (Raetz and Whitfield, 2002). The genes encode the catalytic enzymes for ADP-L-glycero-D-manno-heptose and core-lipid A biosynthesis are presented in
rectangular boxes.
2011; Chou et al., 2013). C. elegans strains were maintained
on nematode growth medium (NGM) agar plates using the
standard nonpathogenic E. coli strain OP50 and synchronized
with alkaline hypochlorite solution as described (Brenner,
1974).
Survival Analysis
All survival assays were conducted as previously described (Chou
et al., 2013). In brief, EHEC was cultured in Luria-Bertani
(LB) broth overnight at 37◦C. Thirty to fifty synchronized late
L4 to young adult stage C. elegans animals were transferred
to each NGM agar plate, which was spread with the 30 µl
bacterial overnight cultures and kept at 20◦C. Animals were
monitored daily and transferred to fresh plates daily until no
more progeny were produced. Animals that did not respond to
gentle prodding by platinum wire and displayed no pharyngeal
pumping were scored as dead. Survival was monitored over
time until all animals had died. The experiment was performed
independently three times with approximately 100 animals per
EHEC strain each time. Survival analysis was performed using
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The
Mantel-Cox logrank test was used to assess statistical significance
of difference in survival, and P < 0.05 were considered
significant.
LPS Extraction and Visualization
Lipopolysaccharides of EHEC were prepared by a hot phenol–
water method as described (Chang et al., 2011), resolved on
12% SDS–polyacrylamide gels and visualized by silver staining as
described previously (Yan et al., 2000).
Bacterial Colonization
Experimental procedures were performed as described (Chou
et al., 2013). For the Green fluorescent protein (GFP) image
analysis, synchronized late L4 to young adult stage C. elegans
animals (N2 or DA597) were fed with either GFP-labeled
E. coli OP50, E. coli O157:H7 EDL933, EDL933:∆rfaD or
EDL933:∆rfaD-prfaD bacteria for 1 day at 20◦C and then
transferred to non GFP-labeled E. coli OP50 bacterial plates
for another 3 days. The infected animals were collected and
mounted on glass slides with 2% agarose pads and anesthetized
with 25 nM sodium azide (NaN3). Colonization of the GFP-
labeled bacteria in the animals was imaged by a Nikon Eclipse
Ti inverted microscope system and quantified. For the colony
forming unit (CFU) analysis, the infected animals were washed
out from the plates, treated with 25mM levamisole and washed
in M9 medium 10 times. To eliminate the bacteria outsite
of the animals, the infected animals were then treated with
M9 buffer containing 25mM levamisole, 100µg/ml gentamicin,
and 1mg/ml ampicillin for 1–2 h at room temperature. These
antibiotics were eliminated by washing the worms in M9 buffer
with 25mM levamisole 3 times. Ten animals were picked
randomly into 100 µl M9 buffer, pulverized for 1 minute using a
sterile plastic pestle, and plated on LB agar containing ampicillin
after serial dilution. The numbers of bacterial colonies were
counted the next day and the colony forming unit (CFU) per
animal was calculated.
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Microvillar ACT-5 Cellular Localization
EHEC induces A/E lesion characterized by the effacement of
intestinal microvilli and the rearrangement of actin cytoskeleton
in the host intestinal cells. ACT-5 is the main actin isoform
that constitutes the intestinal microvilli in C. elegans (MacQueen
et al., 2005). To test whether EHEC induces intestinal microvillar
actin rearrangement, we analyzed distribution of the mCherry-
tagged ACT-5 in C. elegans as previously described (Chou
et al., 2013). In brief, the GK454 animals, with the dkIs247(act-
5p::mCherry::HA::act-5) transgene were fed with E. coli OP50,
E. coli O157:H7 EDL933, EDL933 rfaD::Tn5, EDL933:∆rfaD,
or EDL933:∆rfaD-prfaD for 4 days and the mislocalization of
the mCherry::ACT-5 signals from the apical membrane to the
cytoplasm of the intestinal cells (ectopic ACT-5 localization) was
examined. The infected animals were paralyzed by the method
described above and images were captured by Nikon C1-Si
confocal microscope.
Serum Killing Assay
Experiments followed the procedures previously described
(Wang et al., 2012). Briefly, Log-phase bacteria (∼105 CFU)
were incubated in 100 µl of 10% normal human serum (NHS)
or heat-inactivated normal human serum (HNHS) diluted in
PBS at 37◦C. Aliquots (10 µl) were collected after 60 min, and
each sample was spread on to an LB agar plate. After culturing
overnight, the bacterial numbers were counted. The survival
ratios were calculated by the ratio of the bacterial counts to those
of the originally inoculated.
In vivo and Ex vivo Imaging Analysis of
EHEC Infected Mice
The experiments were approved by the Institutional Animal Care
and Use Committee of National Cheng Kung University (NCKU)
(Approval number 102-209 and 104-039), and all experiments
were carried out in accordance with the approved guidelines and
regulations. Experiments were conducted as described previously
with slight modifications (Rhee et al., 2011). In brief, the 6-
week-old C57BL/6 female mice were purchased and maintained
at the Laboratory Animal Center of NCKU. Mice were supplied
with drinking water containing streptomycin sulfate (5 g/L) for
24 h and then switched to regular water for another 24 h
before infection. Bacteria transformed with pWF279 (luciferase
expressing plasmid) were cultured overnight at 37◦C in LB
medium and diluted in 1:100 in LB medium for 2.5–3 h at 37◦C.
Bacteria then were centrifuged and washed with sterile normal
saline twice and the bacterial concentration was adjusted to
approximately 109 CFU/100 µl in normal saline for mouse oral
gavage with a 22 gage, ball-tipped feeding needle. The bacterial
concentrations were confirmed by plating on LB agar plates.
One hour after oral inoculations, the bioluminescent signals in
infected mice were examined by Xenogen IVIS 200 imaging
system under anesthesia by inhalation of 2.5% isoflurane with
1.5L/min oxygen. Two days post-infection, the bioluminescent
signals in the mice were examined again. The mice were then
euthanized by cervical dislocation by trained personnel and the
entire intestines of infected mice were removed, positioned on a
9 cm Petri dish and imaged by IVIS ex vivo.
Susceptibility to Antimicrobial Peptides
LL-37 peptide (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLV
PRTES) was synthesized by MDBio, Taiwan. The purity (>97%)
and molecular weight were confirmed by high performance
liquid chromatography and mass spectroscopy. Polymyxin B
(catalog number: P0972) and Colistin (catalog number: C4461)
were purchased from Sigma-Aldrich. In order to test the
susceptibility of EDL933 rfaD mutants to AMPs, including LL-
37, Polymyxin B and Colistin, we measured the bacterial growth
with different dosages of AMPs by the microtiter broth dilution
method as described (Giacometti et al., 2000; Thwaite et al.,
2006; Wiegand et al., 2008). In brief, 37◦C overnight bacterial
culture in cation-adjusted Mueller Hinton (MH) medium was
diluted in 1:100 in MH medium and further cultured at 37◦C
for 2.5–3 h. The bacteria in the exponential phase were then
adjusted to approximately 104 CFU/100 µl by MH medium.
Microtiter plates were prepared with serial concentrations of
AMPs, ranging from 1.5625 to 100µg/ml for LL-37 inMH broth.
A suspension containing 100 µl of diluted bacteria (104 CFU)
was added to a well of a 96-well microtiter plate containing
peptide, and then the plate was incubated at 37◦C for 16 h.
Bacterial growth was determined by measuring the absorbance
at 595 nm with a Multiskan FC microplate photometer (Thermo
Scientific), or by the OD-monitor (TAITEC, Japan). The
bacterial CFU were confirmed by plating on the LB agar
plates.
Data Analysis
All experiments were performed a minimum of three times
independently. Statistical analysis between two values was
compared with a paired t-test, and among three or more values
of one independent variable was done with matched one-way
ANOVA with Tukey’s method and more than two independent
variables by two-way ANOVA with the Bonferroni post test. All
data analysis was performed using SPSS, ver 13.0 (SPSS, Chicago,
IL). Statistical significance was set at P < 0.05.
RESULTS
Disruptions of the rfaD and Core LPS
Biosynthesis Genes Decrease Toxicity of
EHEC O157:H7 to C. elegans
LPS has been reported to play important roles in the pathogenesis
of many pathogenic bacteria, including EHEC (Miyashita et al.,
2012). From a genetic screen for identification of attenuated
EHEC mutants in C. elegans (unpublished results), we have
identified an EHEC mutant strain YQ033 (EDL933 rfaD::Tn5)
in which the rfaD gene was disrupted by a Tn5 transposon
insertion in the EHEC O157:H7 strain EDL933. In order to
confirm the notion that ablation of the rfaD gene attenuated
the toxicity of EHEC, we generated an EDL933 isogenic mutant
with rfaD deletion (EDL933:∆rfaD) and tested the toxicity of the
rfaD deletion mutant along with the Tn5 transposon mutant in
C. elegans. As shown in Figure 2A, C. elegans N2 animals fed
with EHEC O157:H7 strain EDL933 had significantly shorter life
spans than if fed with E. coli strainOP50 (P< 0.001), the standard
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FIGURE 2 | Disruptions of rfaD and the genes involved in EHEC core LPS biosynthesis confer attenuated toxicity. (A–D) Survival curves of N2 animals fed
with E. coli strain OP50 (OP50), EHEC strain EDL933 (EDL933), and EDL933 with Tn5 transposon insertion in rfaD (EDL933 rfaD::Tn5), rfaD deletion (EDL933:∆rfaD),
rfaE deletion (EDL933:∆rfaE) and rfaC deletion (EDL933:∆rfaC), and EDL933:∆rfaD with prfaD complementation (EDL933:∆rfaD-prfaD) were examined. All survival
experiments were conducted independently at least three times with approximately 100 animals each time. (A) Animals feeding on the EDL933 rfaD::Tn5 mutant
plates (P < 0.001) and the EDL933:∆rfaD plates (P < 0.001) lived significantly longer than animals feeding on the wild-type EDL933 plates. (B) N2 animals fed with
EDL933:∆rfaE (P < 0.001) lived significantly longer than animals fed with the wild-type EDL933, but were similar to those fed with EDL933:∆rfaD (P = 0.100). (C)
Animals feeding on EDL933:∆rfaC plates (P < 0.001) lived significantly longer than animals feeding on the wild-type EDL933 plates, but were similar to those on
EDL933:∆rfaD (P = 0.938). (D) N2 animals fed with EDL933:∆rfaD (P < 0.001) lived significantly longer than animals fed with EDL933 wild type. The survival curve of
N2 animals fed with EDL933:∆rfaD-prfaD was similar to that of wild-type EDL933 (P = 0.128). (E) Growth curves of wild-type EDL933 and rfaD mutants in LB broth at
37◦C. Both the growth kinetic curves of EDL933:∆rfaD and EDL933:∆rfaD-prfaD, were similar to wild-type EDL933. (F) The LPS samples of OP50, EDL933, EDL933
rfaD::Tn5, EDL933:∆rfaD, and EDL933:∆rfaD-prfaD was examined by silver staining. O-antigens are indicated by the black arrow.
nonpathogenic food source for C. elegans. However, when fed
with both EDL933:∆rfaD (P < 0.001) and EDL933 rfaD::Tn5
(P < 0.001), C. elegans N2 animals lived significantly longer than
animals fed with wild-type EDL933. These results suggest that
disruption of the core LPS biosynthesis genes, including rfaD,
confer less virulence of EHEC toward C. elegans.
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In order to strengthen our hypothesis that altering the EHEC
core LPS biosynthesis genes attenuated toxicity, we generated
the EDL933 isogenic mutants with rfaE (also known as gmhC
and encoding the upstream enzyme of RfaD in the core
LPS synthesis pathway, Figure 1B) deletion (EDL933:∆rfaE)
or rfaC (which encodes the downstream enzyme of RfaD,
Figure 1B) deletion (EDL933:∆rfaC), and tested their virulence
toward C. elegans (Figures 2B,C, respectively). N2 animals lived
significantly longer feeding on EDL933:∆rfaE plates (P < 0.001)
and EDL933:∆rfaC plates (P < 0.001) compared to those on
the wild-type EDL933 plates. Moreover, the survival curve
of N2 animals fed with EDL933:∆rfaD was similar to that
with EDL933:∆rfaE or EDL933:∆rfaC. Taken together, the data
demonstrated that the EHEC core LPS is required for its toxicity
in C. elegans.
In order to reconfirm the role of rfaD in EHEC virulence
against C. elegans, we complemented the rfaD deletion in
the EDL933:∆rfaD mutant by transformation of the RfaD
protein expression plasmid, prfaD. As a result, the survival
curve of N2 animals fed with the prfaD complement strain,
EDL933:∆rfaD-prfaD, was significantly different from that of
animals fed with EDL933:∆rfaD (P < 0.001), and was similar
to that of animals fed with wild-type EDL933 (P = 0.128)
(Figure 2D). Our data demonstrated that the attenuated toxicity
of the rfaD deletion mutant in C. elegans was completely
rescued by the RfaD expression plasmid. An interpretation
for the rfaD deletion in EDL933 resulting in the attenuation
of its virulence is that disruption of RfaD and the core
LPS biosynthesis affects the general physiology of EHEC,
i.e., the growth of bacterial cells. In order to address this
question, we directly analyzed the growth kinetic curves
of wild-type EDL933, EDL933:∆rfaD and EDL933:∆rfaD-
prfaD bacteria. As shown in Figure 2E, the growth kinetics
of EDL933:∆rfaD mutant exhibited no significant difference
to that of wild-type EDL933 and EDL933:∆rfaD-prfaD
bacteria. Taken together, our results suggested that ablation
of rfaD leading to attenuation of EHEC is due to an
unidentified mechanism other than retardation of bacterial
growth.
To examine whether disruption of the rfaD gene in
EDL933 affects its LPS composition, we also isolated the
LPS from OP50, EDL933, EDL933 rfaD::Tn5, EDL933:∆rfaD,
and EDL933:∆rfaD-prfaD bacteria. These LPS samples were
resolved and visualized (Figure 2F). EDL933 mutant strains with
transposon insertion and deletion in the rfaD gene lacked the
O-antigen, but the wild-type EDL933 and EDL933:∆rfaD-prfaD
bacteria contained intact O-antigen. These data reconfirmed that
the LPS structures were altered in these EHEC rfaD mutants.
Moreover, the nonpathogenic E. coliOP50 also lacked O-antigen,
which was in agreement with a previous report (Darby, 2005).
In order to examine the role of rfaD gene per se in the virulence
of E. coli and to test whether C. elegans lives longer feeding on
the rfaDmutant of nonpathogenic E. coli, we generated the OP50
isogenic mutant with rfaD deletion (OP50:∆rfaD) and tested the
virulence. N2 animals fed with OP50:∆rfaD exhibited a similar
survival curve to those fed with wild-type OP50 (P = 0.795)
(Figure S1). Taking the above data together, our results indicated
that the genes involved in core LPS biosynthesis of EHEC strain
EDL933, especially rfaD, are required for EDL933 infection in
C. elegans.
In order to test whether the role of rfaD in the virulence
against C. elegans is general to E. coliO157:H7, we also generated
rfaDmutant in a clinical E. coliO157:H7 isolated strain HER1266
(HER1266:∆rfaD). As shown in Figure S2, C. elegans fed with
HER1266:∆rfaD exhibited a significantly longer life span (P <
0.001) compared to that fed with wild-type HER1266. Moreover,
the prfaD complement strain (HER1266:∆rfaD-pfraD) was
significantly more toxic than the HER1266:∆rfaD (P < 0.001)
and showed no statistical difference compared to the wild-type
HER1266 (P = 0.088). Collectively, our data corroborated the
notion that deletion of the rfaD gene attenuates the toxicity
of E. coli O157:H7 in C. elegans. Moreover, the other two LPS
biosynthesis mutants, EDL933 waaI::Tn5 (waaI encodes the
α-1,3-D-galactosyltransferase and acts downstream of RfaD in
O-oligosaccharide biosynthesis) and EDL933 wbdP::Tn5 (wbdP
encodes a putative glycosyltransferase in O-antigen biosynthesis)
also exhibited significant attenuated toxicity toward C. elegans
(Figure S3). All together, our results indicated that the genes
involved in LPS biosynthesis, including rfaD, are required for
EHEC infection in C. elegans.
Mutation in rfaD Confers Reduced
Bacterial Colonization and Less Microvillar
Actin Rearrangement in the Intestine of
C. elegans
E. coli O157:H7 is an enteric pathogen, which can colonize in
the gastrointestinal tract of humans. We have demonstrated that
EDL933 colonizes in the intestine of C. elegans (Chou et al.,
2013). Therefore, we next examined whether EDL933:∆rfaD
reduces its colonization in the intestine of C. elegans. N2
animals were fed with green fluorescent protein (GFP) labeled
OP50, EDL933, EDL933:∆rfaD or EDL933:∆rfaD-prfaD for
1 day and transferred to normal non-GFP-labeled OP50 for
another 3 days. As shown in Figures 3A–D, the N2 animals
pulsed previously with GFP-labeled EDL933 and GFP-labeled
EDL933:∆rfaD-prfaD showed enhanced GFP signals in their
intestinal tract after chasing with non-GFP-labeled OP50.
However, GFP signals were not detectable in the alimentary
tract of the animals fed with either GFP-labeled OP50 or GFP-
labeled EDL933:∆rfaD previously. N2 animals fed with wild-
type EDL933 and EDL933:∆rfaD-prfaD were smaller, paler
and had an unhealthy apperance compared to animals fed
with OP50 and EDL933:∆rfaD. Moreover, the average colony
formation units (CFU) of the animals pulsed with GFP-labeled
EDL933:∆rfaD or EDL933 rfaD::Tn5 for 1 day and then chased
with non-GFP-labeled OP50 for 3 days were significantly reduced
(P < 0.001) compared to that of the control GFP-labeled
EDL933 fed animals (Figure 3E). The rfaD complementation
group showed a significantly increased intestinal colonization
phenotype compared to the rfaD mutants (EDL933:∆rfaD and
EDL933 rfaD::Tn5). These data demonstrated that mutations
in rfaD reduce the intestinal colonization ability of EDL933 in
C. elegans.
EHEC induced host A/E (attaching and effacing) lesion in
intestinal tract, which caused cytoskeleton actin rearrangement
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FIGURE 3 | Mutation in rfaD reduces EDL933 colonization in C. elegans. Images of wild-type N2 nematodes fed with GFP-labeled OP50 (A), EDL933 (B),
EDL933: ∆rfaD (C) or EDL933:∆rfaD-prfaD (D) for 1 days at 20◦C and then chased with non GFP-labeled OP50 for 3 days at 20◦C, respectively. Animals previously
exposed on GFP-labeled EDL933 and EDL933:∆rfaD-prfaD plates showed significant GFP signals in their intestines. Animals fed with wild-type EDL933 and
EDL933:∆rfaD-prfaD exhibited unhealthy apperances with smaller and paler body compared to animals fed with OP50 and EDL933:∆rfaD. Representative images
are shown, and the scale bar represents 100 µm. (E) The number of bacteria colonized in C. elegans was determined by the colony forming units (CFU) assay. Values
represent the means of three independent assays, and error bars indicate the standard deviations. P-values denote the results of statistical analysis. The total
numbers of animals tested in each group are indicated by n.
in host intestinal cells. Our previous report demonstrates that the
transgenic C. elegans animals expressing mCherry-tagged ACT-5
can serve as a good model to monitor EHEC-induced microvillar
actin rearrangement in intestinal cells (Chou et al., 2013). We
examined the mCherry signals of the transgenic C. elegans
animals fed with wild-type EDL933 and rfaDmutants by confocal
microscopy. As shown in Figure 4A, the mCherry::ACT-5
animals fed with wild-type EDL933 for 4 days at 20◦C exhibited
significant ectopic mCherry::ACT-5 signals from apical plasma
membrane to the cytoplasm. However, the mislocalozation of
ACT-5 significantly decreased in the animals fed with the rfaD
mutants (EDL933:∆rfaD and EDL933 rfaD::Tn5) compared to
that with wild-type EDL933. The transgenic animals fed with
EDL933:∆rfaD-prfaD showed a similar phenotype to that of
wild-type EDL933. Quantifications of animals with the ectopic
mCherry::ACT-5 signal after the exposure to wild-type EDL933
and rfaD mutants were also determined (Figure 4B). The data
showed that the rfaD mutants are significantly less virulent to
C. elegans animals in terms of the induction of A/E lesions.
Taking the above data together, we demonstrated that the rfaD
mutations confer attenuation of EHEC to C. elegans in vivo.
Disruption of rfaD Reduces Bacterial
Colonization in the Intestine of Mouse
We next tested whether deletion of the rfaD gene in EHEC
also confers less intestinal colonization in mammals. To this
end, we generated the bioluminescence-labeled wild-type
EDL933, EDL933:∆rfaD and EDL933:∆rfaD-prfaD bacteria by
transformation of the luciferase expressing plasmid, pWF279,
and examined the bioluminescent signal by the non-invasive in
vivo imaging system (IVIS) after oral gavage of approximately
109 CFU bioluminescent bacteria into 6 week-old female
C57BL/6 mice pretreated with streptomycin (Figure 5). The
mice infected intragastrically with bioluminescence-labeled
wild-type EDL933, EDL933:∆rfaD and EDL933:∆rfaD-prfaD
exhibited similar bioluminescent signal levels 1 h post infection
(Figures 5A,B). While, the mice infected with bioluminescence-
labeled wild-type EDL933 and EDL933:∆rfaD-prfaD revealed
significant bioluminescent signals 2 days post infection
However, the bioluminescent signals of mice infected with
EDL933:∆rfaD were significantly decreased after 2 days post
infection (Figures 5C,D).
Next, we determined the localization of these
bioluminescence-labeled bacteria. The intestines of mice 2
days post infection were removed and imaged by IVIS ex vivo.
As shown in Figure 5E, the bioluminescent signals of wild-type
EDL933 and EDL933:∆rfaD-prfaD bacteria were detected in
the cecum and colon, which suggest that EHEC can colonize
in the cecum and colon of mice for at least 2 days, while the
bioluminescent signal was not detectable in the intestines of mice
infected by EDL933:∆rfaD. The quantification of bioluminescent
signals showed similar results, i.e., the bioluminescent signals
were significantly decreased in the EDL933:∆rfaD treated
mice compared to the wild-type EDL933 (P < 0.01) and
EDL933:∆rfaD-prfaD (P < 0.01) treated groups (Figure 5F).
Taken together, these data demonstrated that the abolishment of
functional rfaD reduces EDL933 colonization to the intestine,
specifically in the cecum and colon, of mouse. Given that
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FIGURE 4 | Mutations in rfaD reduce EHEC-induced intestinal microvillar actin rearrangement in C. elegans. (A) The confocal images showed the
mCherry-tagged ACT-5 (intestinal microvillar actin) of GK454 transgenic animals fed with OP50, EDL933, EDL933 rfaD::Tn5 (rfaD::Tn5), EDL933:∆rfaD (∆rfaD) or
EDL933:∆rfaD-prfaD (∆rfaD-prfaD) for 4 days respectively. Ectopic localization of the mCherry::ACT-5 signals from the apical membrane to the cytoplasm of the
intestinal cells were significantly increased in the EDL933 treated group. Upper panels show mCherry images; lower panels are the merge images of the DIC and
mCherry signals. Representative images are shown, and scale bar represents 10 µm. (B) Quantifications of animals with the EHEC-induced ectopic mCherry::ACT-5
signal were determined. Values represent the means of three independent assays, and error bars indicate the standard deviations. P-values denote the results of
statistical analysis.
EHEC is considered less virulent to mouse when infected orally
(Mohawk and O’Brien, 2011), our data also suggested that loss
of core LPS in EHEC may increase its susceptibility to host
intestinal immunity and therefore accelerate the elimination rate
of bacterial cells from the host body.
Deletion of rfaD Increases the
Susceptibility of EHEC to Human Serum
Killing
One characteristic of EHEC virulence is its serum resistance.
Several virulence factors encoded by EHEC, including the iss,
traT, and stcE genes, which confer EHEC serum resistance
have been documented (Binns et al., 1979, 1982; Lathem et al.,
2004). Chain length of LPS has also been reported to affect
serum resistance in Salmonella (Bravo et al., 2008). However, the
correlation between E coli O157:H7 LPS and serum resistance
remains poorly understood. To assess whether the LPS protects
EHEC from serum killing, we monitored the survival rate of
EHEC cells in the presence of human serum. The relative
survival ratios of EDL933, EDL933 rfaD::Tn5, EDL933:∆rfaD,
and EDL933:∆rfaD-prfaD in either 10% normal human serum
(NHS) or 10% heat-inactivated normal human serum (HNHS)
were measured. In HNHS, the complement system in normal
serum was inactivated after the pre-incubation of NHS at 56◦C
for 30 min. As shown in Figure 6A, the wild-type EDL933 cells
exhibited a significantly greater survival ratio compared to the
rfaD transposon mutant (EDL933 rfaD::Tn5, P = 0.001) and
rfaD deletion mutant (EDL933:∆rfaD, P = 0.001) in 10% NHS
at 37◦C for 1 h. The wild-type EDL933 cells still replicated
(1.94 fold increase) in 10% NHS, but the EDL933 rfaD::Tn5
and EDL933:∆rfaD cells were killed in the presence of NHS
(0.03 fold and 0.02 fold, respectively). The rfaD complement
(EDL933:∆rfaD-prfaD) cells rescued the serum resistance defect
of the rfaD mutation and showed similar survival ratio (1.21
fold increase, P = 0.101) compared to wild-type EDL933 cells.
Together, our data demonstrated that rfaD is required for EHEC
serum resistance.
When these bacterial cells were cultured in 10% HNHS
(Figure 6B), the wild-type EDL933 (1.90 fold increase) and
EDL933:∆rfaD-prfaD cells (1.99 fold increase) still replicated
normally. The survival ratios of these two strains in 10% HNHS
and 10% NHS were similar (EDL933, P= 0.937; EDL933:∆rfaD-
prfaD, P = 0.05), which supports the notion that EHEC is
serum resistant. Moreover, both the rfaD transposon mutant
and deletion mutant showed significantly greater ability to
survive in 10% HNHS (0.82 fold and 0.94 fold, respectively)
than in 10% NHS (0.03 fold and 0.02 fold, respectively).
These data demonstrated that rfaD is required for the defense
of the complement system in human serum. Interestingly,
the survival ratios of the rfaD mutants (EDL933 rfaD::Tn5,
P = 0.031 and EDL933:∆rfaD, P = 0.034) were still significantly
decreased compared to the wild-type EDL933 in 10% HNHS
(Figure 6B). These data suggested that the rfaD mutants are still
hypersusceptible to the complement-independent killing effect of
normal human serum compared to wild-type EDL933.
Disruptions of rfaD Increase the
Susceptibility of EHEC to AMPs In vitro
Antimicrobial peptides (AMPs) are short peptides that inhibit
bacterial cell growth and constitute a host innate immune system
against bacterial infection. AMPs target the bacterial membrane
and disrupt the membrane integrity of bacteria cells, and the
lack of the protection of LPS barrier leads AMPs to target
the bacteria membrane more easily (Rosenfeld and Shai, 2006;
Bahar and Ren, 2013). It has been reported that mammalian
serum contains a variety of AMPs, including Cathelicidin, and
still maintains antibiotic activity after 65◦C treatment (Mahoney
et al., 1995), which resembles the complement-independent
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FIGURE 5 | Disruption of rfaD reduces EDL933 colonization in the intestines of mice. (A) Represent images of mice inoculated with bioluminescence-labeled
wild-type EHEC EDL933 (EDL933), EDL933:∆rfaD (∆rfaD), and EDL933:∆rfaD-prfaD (∆rfaD-prfaD) 1 h post infection. (B) Quantification of bioluminescence intensity
of mice infected with EDL933, EDL933:∆rfaD and EDL933:∆rfaD-prfaD 1 h post infection. (C) Represent images of mice inoculated with bioluminescence-labeled
wild-type EHEC EDL933 (EDL933), EDL933:∆rfaD (∆rfaD), and EDL933:∆rfaD-prfaD (∆rfaD-prfaD) 2 days post infection. (D) Quantification of bioluminescence
intensity of mice infected with EDL933, EDL933:∆rfaD and EDL933:∆rfaD-prfaD 2 days post infection. (E) Represent images of intestinal tissues of mice infected with
bioluminescence-labeled wild-type EHEC EDL933 (EDL933), EDL933:∆rfaD (∆rfaD), and EDL933:∆rfaD-prfaD (∆rfaD-prfaD). (F) Quantification of bioluminescence
signals of intestinal tissues of bioluminescent EHEC infected mice 2 days post infection. The color scale represents the radiance (p/sec/cm2/sr). Representative
images are shown. All experiments were conducted independently three times with 3 animals each time, and error bars indicate the standard deviations.
innate immunity that inhibited the growth of rfaD mutants in
the 56◦C heat-inactivated human serum (Figure 6B). In order
to test whether disruption of rfaD could alter the susceptibility
of EHEC to AMPs, we cultured the wild-type EDL933 and rfaD
mutants in the presence of LL-37, a short peptide with the
bactericidal function derived from the Cathelicidin family of
AMP (Vandamme et al., 2012; Wang, 2014), and examined their
growth kinetics in vitro. The minimum inhibitory concentrations
(MIC) of LL-37 against the rfaD mutants, including EDL933
rfaD::Tn5 (6.25 µg/ml), and EDL933:∆rfaD (6.25 µg/ml),
were significantly lower than that of wild-type EDL933 (>100
µg/ml) and EDL933:∆rfaD-prfaD (>100 µg/ml) (Figure 6C).
The growth kinetics of bacteria cultured with LL-37 also showed
that LL-37 significantly inhibits the replication of EDL933
rfaD::Tn5, and EDL933:∆rfaD cells (Figure 6D). Moreover, the
rfaD mutations also increased the susceptibility of EDL933 to
the other two AMPs, Polymyxin B and Colistin (all P < 0.05,
Table S3). Together, our data demonstrated that disruption of
rfaD increases the susceptibility of EHEC to AMPs in vitro.
Deletion of rfaD Confers the
Hypersusceptibility of EHEC to Host
Intestinal Immunity In vivo
We showed that the GFP-labeled wild-type EDL933 can replicate
and colonize in the intestinal lumen of C. elegans; however,
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FIGURE 6 | Deletion of EHEC rfaD increases its susceptibility to human serum killing and the antimicrobial peptide LL-37. The fold changes of bacterial
cell numbers of wild-type EDL933, EDL933 rfaD::Tn5, EDL933:∆rfaD and EDL933:∆rfaD-prfaD after incubation in 10% normal human serum (NHS) (A) or 10%
heat-inactivated normal human serum (HNHS) (B) at 37◦C for 60 min were measured. Experiments were conducted independently at least three times, and error bars
indicate the standard deviations. (A) The rfaD transposon mutant (rfaD::Tn5, P = 0.001) and rfaD deletion mutant (∆rfaD, P = 0.001) showed significant decreased
survival ratio compared to that of wild-type EDL933 (EDL933) in 10% NHS. The rfaD complement bacteria (∆rfaD-prfaD) showed comparable survival ratio compared
to that of EDL933 (P = 0.101) in 10% NHS. (B) The rfaD transposon mutant (rfaD::Tn5, P = 0.031) and rfaD deletion mutant (∆rfaD, P = 0.034) showed significantly
decreased survival ratio compared to that of wild-type EDL933 (EDL933) in 10% HNHS. The rfaD complement bacteria (∆rfaD-prfaD) showed comparable survival
ratio compared to that of EDL933 (P = 0.854) in 10% HNHS. n.s. indicates no statistical significance. (C) The OD595 values of wild-type EDL933 (EDL933), EDL933
rfaD::Tn5 (rfaD::Tn5), EDL933:∆rfaD (∆rfaD), and EDL933:∆rfaD-prfaD (∆rfaD-prfaD) cultured with different dose of LL-37 at 37◦C for 16 h were monitored. (D) The
growth curves of EDL933, rfaD::Tn5, ∆rfaD and ∆rfaD-prfaD in the presence of 12.5 µg/ml LL-37 at 37◦C.
the GFP-labeled rfaD mutants cannot (Figure 3). Given that
C. elegans is a bacterivore and most of the bacteria cells
ingested are ground up by the pharynx of C. elegans, another
interpretation of these results is that the physiological integrity
of the outer membrane in the rfaDmutants is weak and therefore
makes themmore vulnerable to the grinding force of the pharynx,
other than simply increasing their susceptibility to innate
immunity in the intestine of C. elegans. In order to test whether
rfaD mutants are directly hypersusceptible to the intestinal
antimicrobial immunity in vivo, we monitored the replication
and colonization of the rfaD mutants in the pharynx-defect
C. elegans strain DA597 (Figure 7). The DA597 animals contain
two mutations in the phm-2(ad597) allele that result in abnormal
position and function of the pharyngeal grinder (Avery, 1993).
When DA597 animals were pulsed with GFP-labeled OP50,
wild-type EDL933, EDL933:∆rfaD, or EDL933:∆rfaD-prfaD
bacteria for 1 day, most of the animals exhibited GFP signals
in their intestine and there was no significant difference
among different bacteria-treated groups (Figures 7A–E). The
data suggested that these GFP-labeled bacteria can pass into
the intestinal lumen without being damaged by the pharynx
in DA597 animals. However, when these GFP-labeled bacteria
infected animals were further chased with non-GFP-labeled
OP50 for another 3 days (Figures 7F–J), only DA597 animals
infected previously by GFP-labeled wild-type EDL933 and
EDL933:∆rfaD-prfaD still maintained significant GFP signals
in their intestines. However, the GFP signals were totally
abolished in the GFP-labeled OP50 and EDL933:∆rfaD-infected
groups. These data support the notion that the EDL933:∆rfaD,
similar to the non-pathogenic OP50, is hypersensitive to the
intestinal innate immunity in C. elegans, and are therefore
quickly killed and eliminated by the animals in vivo. This
phenomenon is similar to that in mice described in Figure 5.
Together, our results suggested that disruptions of the rfaD
gene increased the susceptibility of EHEC to host intestinal
immunity.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 10 August 2016 | Volume 6 | Article 82
Kuo et al. EHEC and Host Intestinal Immunity
FIGURE 7 | The rfaD mutation increases the susceptibility of EHEC to host intestinal innate immunity. Images of DA597 pharynx defect C. elegans fed with
(A) GFP-labeled OP50 (OP50-GFP), (B) EDL933 (EDL933-GFP), (C) EDL933:∆rfaD (∆rfaD-GFP), or (D) EDL933:∆rfaD-prfaD (∆rfaD-prfaD-GFP) at 20◦C for 1 day.
(E) Percentage of GFP-labeled bacteria (A–D) fed DA597 animals with GFP signals in intestine was calculated. Images of DA597 animals fed with (F) GFP-labeled
OP50, (G) EDL933, (H) EDL933:∆rfaD, or (I) EDL933:∆rfaD-prfaD at 20◦C for 1 days and chased on normal non-GFP OP50 plates for 3 days. (J) Percentage of
GFP-labeled bacteria (F–I) fed DA597 animals with GFP signals in intestine was calculated. All experiments were conducted independently at least three times, and
error bars indicate the standard deviations. The scale bar represents 100 µm.
DISCUSSION
Our genetic analyses in the present study demonstrate that rfaD
and genes involved in the LPS biosynthesis are required for
EHEC infection in C. elegans. Disruption of E. coli O157:H7
LPS attenuates its toxicity to C. elegans. The E. coli O157:H7
rfaDmutants are significantly less virulent to C. elegans animals,
as shown by significantly reduced bacterial colonization and
microvillar actin rearrangement in the alimentary tract of C.
elegans. Moreover, mutation of rfaD diminishes the colonization
of E. coli O157:H7 in the intestine, specifically in the cecum and
colon, in mouse. Our mechanistic study demonstrates that the
attenuated phenotype of E. coli O157:H7 rfaD mutant to animal
hosts may, at least in part, be due to an increase in susceptibility
to antimicrobial peptides and host intestinal immunity in vivo.
The enzymatic product of RfaD, ADP-L-glycero-D-manno-
heptose, links core LPS and O-antigen to Kdo2-lipid A on the
EHEC outer membrane (Figure 1). It has been reported that
inhibition of the KdtA (also called WaaA), which links the ADP-
L-glycero-D-manno-heptose to Kdo2-lipid A for the core-lipid A
formation, causes the accumulation of Lipid A Kdo2 disaccharide
on the outer membrane of E. coli (Belunis et al., 1995). Given that
the RfaD is the last step enzyme for ADP-L-glycero-D-manno-
heptose and inner core LPS biosynthesis, inactivation of RfaD
may also result in the accumulation of Kdo2-lipid A on the
EHEC outer membrane. Of note, Kdo2-lipid A has been reported
to stimulate the innate immune system through the Toll-like
receptor 4 (TLR4) signaling pathway (Raetz et al., 2006; Sims
et al., 2010; Kim et al., 2015), and it has been suggested the
E. coli rfaD mutants that produce more Kdo2-lipid A could
be a good base strain for developing bacterial vaccine adjuvant
(Wang et al., 2014). Our results demonstrate that the EHEC rfaD
mutants are significantly attenuated to animal hosts, including
C. elegans and mouse, in vivo, therefore testing whether the
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EDL933:∆rfaDmutants can activate the innate immune response
is warranted and the potential for these mutants in EHEC vaccine
development is suggested.
In metazoans, including C. elegans and mammals, host
antimicrobial peptides (AMPs) are crucial components of the
innate immune system (Irazoqui et al., 2010; Nakatsuji and
Gallo, 2012; Pukkila-Worley and Ausubel, 2012). Humans
have approximately one hundred AMPs, and these AMPs
have been found on the mucus surface layer of a variety of
tissues, including intestine (Wang, 2014). It has been reported
that the AMP Cathelicidin mediates innate intestinal defense
against colonization with epithelial adherent bacterial pathogens,
including Escherichia coli O157:H7 (Iimura et al., 2005), and
protects mice from EHEC-mediated disease (Chromek et al.,
2012). Our in vitro and in vivo data in Figures 5–7, which suggest
that the EHEC rfaD mutants are hypersensitive to AMPs and
confer less intestinal colonization, are in agreement with these
reports. However, it also has been reported that the EHEC outer-
membrane protease OmpT can degrade the human AMP LL-37
and has evolved as a strategy through which EHEC can resist
AMPs (Thomassin et al., 2012). Our data demonstrated that
targeting RfaD and core LPS biosynthesis can further sensitize
the EHEC cells to AMP killing and host innate immunity, which
are also in agreement with the recent findings (Ho and Waldor,
2007; Sheng et al., 2008; Miyashita et al., 2012; Youn et al., 2013).
Therefore, future testing of whether inhibiting RfaD activity
would affect the expression of OmpT on the outer-membrane of
EHEC is also clinically relevant.
Bacterial pathogens that are resistant to antibiotics have
become an urgent worldwide issue, and the antibiotic resistance
of EHEC has also been reported (Venturini et al., 2010;
Goldwater and Bettelheim, 2012). Pathogens resistant to
currently available antibiotics are increasing drastically, not to
mention that the treatment of EHEC infection by canonical
antibiotics is contraindicated. For decades, targeting LPS
biosynthesis and/or export has been considered as an attractive
strategy for the treatment of Gram-negative pathogens infection
(Cipolla et al., 2011; Walsh and Wencewicz, 2014). However,
antibacterial drugs with this mechanism of action are still under
development and have not yet been used clinically. It has not
escaped our notice that the EHEC rfaD deletion strains are deep
rough LPS mutants (Figure 2F), therefore another interpretation
of our results for the attenuated toxicity of these EHEC LPS
mutants in vivo could attribute to their general weakness.
Nevertheless, the replication rate/growth kinetics of the rfaD
mutant remained unaffected in vitro (Figure 2E). These data
suggest that the inhibition of RfaD, in part, can sensitize EHEC to
host intestinal immunity and/or microenvironment and enhance
their clearance by host in vivo. Here, our study highlights the
potential of targeting RfaD or the other enzymes in the LPS
biosynthesis pathway, if druggable, as alternative therapeutic
measure by which to combat EHEC infection.
AUTHOR CONTRIBUTIONS
CK, JC, HC, CT, TH, WS, SW, TC, and CC conceived and
designed the experiments. CK, TH, SW, and TC performed the
experiments. CK, JC, HC, CT, SW, TC, and CC analyzed the data.
JC, HC, CT, PL, and WS contributed reagents/materials/analysis
tools. CK and CC wrote the paper.
FUNDING
This work is supported by the Minister of Science and
Technology (MOST) grants (101-2311-B-006-005, 102-2311-B-
006-005, 102-2321-B-006-022, and 104-2321-B-006-019) to CC.
ACKNOWLEDGMENTS
We are grateful to the assistance from the Taiwan C. elegans
core facility, funded by the MOST Taiwan, and feedback
from the Taiwan worm research community. We thank the
Caenorhabditis Genetics Center (CGC), which is supported by
the National Institutes of Health (United States)- Office of
Research Infrastructure Programs (P40 OD010440), for the C.
elegans strains. We acknowledge the proteomics core facility
of the Clinical Medicine Research Center in National Cheng
Kung University Hospital for the silver staining experiment,
and Chi-Chung Chen from the Department of Medical
Research, Chi Mei Medical Center (Tainan, Taiwan) for the
help in mouse infection. We are grateful for the support
from the laboratory animal center of National Cheng Kung
University. We also thank Miranda Loney for editing the
manuscript.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fcimb.
2016.00082
REFERENCES
Anderson, G. L., Kenney, S. J., Millner, P. D., Beuchat, L. R., and Williams,
P.L. (2006). Shedding of foodborne pathogens by Caenorhabditis elegans in
compost-amended and unamended soil. Food Microbiol. 23, 146–153. doi:
10.1016/j.fm.2005.01.018
Armstrong, G. D., Mulvey, G. L., Marcato, P., Griener, T. P., Kahan, M.
C., Tennent, G. A., et al. (2006). Human Serum Amyloid P component
protects against Escherichia coli O157:H7 Shiga Toxin 2 in vivo: therapeutic
implications for hemolytic-uremic syndrome. J. Infect. Dis. 193, 1120–1124.
doi: 10.1086/501472
Avery, L. (1993). The genetics of feeding in Caenorhabditis elegans. Genetics 133,
897–917.
Bahar, A. A., and Ren, D. (2013). Antimicrobial peptides. Pharmaceuticals (Basel)
6, 1543–1575. doi: 10.3390/ph6121543
Belunis, C. J., Clementz, T., Carty, S. M., and Raetz, C. R. H. (1995). Inhibition
of lipopolysaccharide biosynthesis and cell growth following inactivation of the
kdtA gene in Escherichia coli. J. Biol. Chem. 270, 27646–27652. doi: 10.1074/jbc.
270.46.27646
Bentancor, L. V., Bilen, M., Brando, R. J., Ramos, M. V., Ferreira, L.
C., Ghiringhelli, P. D., et al. (2009). A DNA vaccine encoding the
enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 12 August 2016 | Volume 6 | Article 82
Kuo et al. EHEC and Host Intestinal Immunity
protective immunity to Shiga toxin challenge in the murine model. Clin.
Vaccine Immunol. 16, 712–718. doi: 10.1128/CVI.00328-08
Binns, M. M., Davies, D. L., and Hardy, K. G. (1979). Cloned fragments of the
plasmid ColV,I-K94 specifying virulence and serum resistance. Nature 279,
778–781. doi: 10.1038/279778a0
Binns, M. M., Mayden, J., and Levine, R. P. (1982). Further characterization of
complement resistance conferred on Escherichia coli by the plasmid genes traT
of R100 and iss of ColV,I-K94. Infect. Immun. 35, 654–659.
Bravo, D., Silva, C., Carter, J. A., Hoare, A., Alvarez, S. A., Blondel, C. J., et al.
(2008). Growth-phase regulation of lipopolysaccharide O-antigen chain length
influences serum resistance in serovars of Salmonella. J. Med. Microbiol. 57(Pt
8), 938–946. doi: 10.1099/jmm.0.47848-0
Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71–94.
Chang, P. C., Wang, C. J., You, C. K., and Kao, M. C. (2011). Effects of a HP0859
(rfaD) knockout mutation on lipopolysaccharide structure of Helicobacter
pylori 26695 and the bacterial adhesion on AGS cells. Biochem. Biophys. Res.
Commun. 405, 497–502. doi: 10.1016/j.bbrc.2011.01.060
Chou, T. C., Chiu, H. C., Kuo, C. J., Wu, C. M., Syu, W. J., Chiu, W. T., et al.
(2013). Enterohaemorrhagic Escherichia coli O157:H7 Shiga-like toxin 1 is
required for full pathogenicity and activation of the p38 mitogen-activated
protein kinase pathway in Caenorhabditis elegans. Cell. Microbiol. 15, 82–97.
doi: 10.1111/cmi.12030
Chromek, M., Arvidsson, I., and Karpman, D. (2012). The antimicrobial peptide
cathelicidin protects mice from Escherichia coli O157:H7-mediated disease.
PLoS ONE 7:e46476. doi: 10.1371/journal.pone.0046476
Cipolla, L., Polissi, A., Airoldi, C., Gabrielli, L., Merlo, S., and Nicotra, F.
(2011). New targets for antibacterial design: Kdo biosynthesis and LPS
machinery transport to the cell surface. Curr. Med. Chem. 18, 830–852. doi:
10.2174/092986711794927676
Darby, C. (2005). “Interactions with microbial pathogens,” in The C. elegans
Research Community, WormBook. doi: 10.1895/wormbook.1.21.1
Datsenko, K. A., and Wanner, B. L. (2000). One-step inactivation of chromosomal
genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U.S.A.
97, 6640–6645. doi: 10.1073/pnas.120163297
Freedman, S. B., Xie, J., Neufeld, M. S., Hamilton, W. L., Hartling, L., and Tarr, P. I.
(2016). Shiga toxin-producing escherichia coli infection, antibiotics, and risk of
developing hemolytic uremic syndrome: a meta-analysis. Clin. Infect. Dis. 62,
1251–1258. doi: 10.1093/cid/ciw099
Giacometti, A., Cirioni, O., Barchiesi, F., Del Prete, M. S., Fortuna, M., Caselli,
F., et al. (2000). In vitro susceptibility tests for cationic peptides: comparison
of broth microdilution methods for bacteria that grow aerobically. Antimicrob.
Agents Chemother. 44, 1694–1696. doi: 10.1128/aac.44.6.1694-1696.2000
Goldwater, P. N., and Bettelheim, K. A. (2012). Treatment of enterohemorrhagic
Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).
BMCMed. 10:12. doi: 10.1186/1741-7015-10-12
Ho, T. D., andWaldor, M. K. (2007). Enterohemorrhagic Escherichia coliO157:H7
gal mutants are sensitive to bacteriophage P1 and defective in intestinal
colonization. Infect. Immun. 75, 1661–1666. doi: 10.1128/IAI.01342-06
Iimura, M., Gallo, R. L., Hase, K., Miyamoto, Y., Eckmann, L., and Kagnoff, M.
F. (2005). Cathelicidin mediates innate intestinal defense against colonization
with epithelial adherent bacterial pathogens. J. Immunol. 174, 4901–4907. doi:
10.4049/jimmunol.174.8.4901
Irazoqui, J. E., Urbach, J. M., and Ausubel, F. M. (2010). Evolution of host innate
defence: insights from Caenorhabditis elegans and primitive invertebrates. Nat.
Rev. Immunol. 10, 47–58. doi: 10.1038/nri2689
Kenney, S. J., Anderson, G. L., Williams, P. L., Millner, P. D., and Beuchat, L.
R. (2005). Persistence of Escherichia coli O157:H7, Salmonella Newport, and
Salmonella Poona in the gut of a free-living nematode, Caenorhabditis elegans,
and transmission to progeny and uninfected nematodes. Int. J. Food Microbiol.
101, 227–236. doi: 10.1016/j.ijfoodmicro.2004.11.043
Kim, E.-Y., Shin, H. Y., Kim, J.-Y., Kim, D.-G., Choi, Y.-M., Kwon, H.-K., et al.
(2015). ATF3 plays a key role in Kdo2-lipid A-induced TLR4-dependent gene
expression via NF-κB activation. PLoS ONE 5:e14181. doi: 10.1371/journal.
pone.0014181
Lathem, W. W., Bergsbaken, T., and Welch, R. A. (2004). Potentiation of C1
esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli
O157:H7. J. Exp. Med. 199, 1077–1087. doi: 10.1084/jem.20030255
MacQueen, A. J., Baggett, J. J., Perumov, N., Bauer, R. A., Januszewski, T.,
Schriefer, L., et al. (2005). ACT-5 is an essential Caenorhabditis elegans actin
required for intestinal microvilli formation. Mol. Biol. Cell 16, 3247–3259. doi:
10.1091/mbc.E04-12-1061
Mahoney, M. M., Lee, A. Y., Brezinski-Caliguri, D. J., and Huttner, K. M. (1995).
Molecular analysis of the sheep cathelin family reveals a novel antimicrobial
peptide. FEBS Lett. 377, 519–522. doi: 10.1016/0014-5793(95)01390-3
McGhee, J.D. (2007). “The C. elegans intestine,” in The C. elegans Research
Community, WormBook. doi: 10.1895/wormbook.1.133.1
Miyashita, A., Iyoda, S., Ishii, K., Hamamoto, H., Sekimizu, K., and Kaito, C.
(2012). Lipopolysaccharide O-antigen of enterohemorrhagic Escherichia coli
O157:H7 is required for killing both insects and mammals. FEMS Microbiol.
Lett. 333, 59–68. doi: 10.1111/j.1574-6968.2012.02599.x
Mohawk, K. L., and O’Brien, A. D. (2011). Mouse models of Escherichia
coli O157:H7 infection and shiga toxin injection. J. Biomed. Biotechnol.
2011:258185. doi: 10.1155/2011/258185
Nakatsuji, T., and Gallo, R. L. (2012). Antimicrobial peptides: old molecules with
new ideas. J. Invest. Dermatol. 132(3 Pt 2), 887–895. doi: 10.1038/jid.2011.387
Nguyen, Y., and Sperandio, V. (2012). Enterohemorrhagic E. coli (EHEC)
pathogenesis. Front. Cell. Infect. Microbiol. 2:90. doi: 10.3389/fcimb.2012.00090
Pacheco, A. R., and Sperandio, V. (2012). Shiga toxin in enterohemorrhagic E.coli:
regulation and novel anti-virulence strategies. Front. Cell. Infect. Microbiol.
2:81. doi: 10.3389/fcimb.2012.00081
Pennington, H. (2010). Escherichia coli O157. Lancet 376, 1428–1435. doi:
10.1016/S0140-6736(10)60963-4
Pukkila-Worley, R., and Ausubel, F. M. (2012). Immune defense mechanisms in
the Caenorhabditis elegans intestinal epithelium. Curr. Opin. Immunol. 24, 3–9.
doi: 10.1016/j.coi.2011.10.004
Raetz, C. R., Garrett, T. A., Reynolds, C. M., Shaw, W. A., Moore, J. D.,
Smith, D. C. Jr., et al. (2006). Kdo2-Lipid A of Escherichia coli, a defined
endotoxin that activates macrophages via TLR-4. J. Lipid Res. 47, 1097–1111.
doi: 10.1194/jlr.M600027-JLR200
Raetz, C. R., and Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annu. Rev.
Biochem. 71, 635–700. doi: 10.1146/annurev.biochem.71.110601.135414
Rhee, K. J., Cheng, H., Harris, A., Morin, C., Kaper, J. B., and Hecht, G. (2011).
Determination of spatial and temporal colonization of enteropathogenic E. coli
and enterohemorrhagic E. coli in mice using bioluminescent in vivo imaging.
Gut Microbes 2, 34–41. doi: 10.4161/gmic.2.1.14882
Rosenfeld, Y., and Shai, Y. (2006). Lipopolysaccharide (Endotoxin)-host defense
antibacterial peptides interactions: role in bacterial resistance and prevention
of sepsis. Biochim. Biophys. Acta 1758, 1513–1522. doi: 10.1016/j.bbamem.2006.
05.017
Sato, M., Saegusa, K., Sato, K., Hara, T., and Harada, A. (2011). Caenorhabditis
elegans SNAP-29 is required for organellar integrity of the endomembrane
system and general exocytosis in intestinal epithelial cells. Mol. Biol. Cell 22,
2579–2587. doi: 10.1091/mbc.E11-04-0279
Sauter, K. A., Melton-Celsa, A. R., Larkin, K., Troxell, M. L., O’Brien, A. D., and
Magun, B. E. (2008). Mouse model of hemolytic-uremic syndrome caused by
endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by
anti-Stx2 antibody. Infect. Immun. 76, 4469–4478. doi: 10.1128/IAI.00592-08
Sheng, H., Lim, J. Y., Watkins, M. K., Minnich, S. A., and Hovde, C. J. (2008).
Characterization of an Escherichia coli O157:H7 O-antigen deletion mutant
and effect of the deletion on bacterial persistence in the mouse intestine and
colonization at the bovine terminal rectal mucosa. Appl. Environ. Microbiol. 74,
5015–5022. doi: 10.1128/AEM.00743-08
Sheoran, A. S., Chapman-Bonofiglio, S., Harvey, B. R., Mukherjee, J., Georgiou,
G., Donohue-Rolfe, A., et al. (2005). Human antibody against shiga toxin
2 administered to piglets after the onset of diarrhea due to Escherichia coli
O157:H7 prevents fatal systemic complications. Infect. Immun. 73, 4607–4613.
doi: 10.1128/IAI.73.8.4607-4613.2005
Sims, K., Haynes, C. A., Kelly, S., Allegood, J. C., Wang, E., Momin, A., et al.
(2010). Kdo2-Lipid A, a TLR4-specific agonist, induces de novo sphingolipid
biosynthesis in RAW264.7 macrophages, which is essential for induction of
autophagy. J. Biol. Chem. 285, 38568–38579. doi: 10.1074/jbc.M110.170621
Tesh, V. L., Burris, J. A., Owens, J. W., Gordon, V. M., Wadolkowski, E. A. O.,
Brien, A. D., et al. (1993). Comparison of the relative toxicities of shiga-like
toxins type I and type II for mice. Infect. Immun. 61, 3392–3402.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 13 August 2016 | Volume 6 | Article 82
Kuo et al. EHEC and Host Intestinal Immunity
Thomassin, J.-L., Brannon, J. R., Kaiser, J., Gruenheid, S., and Moual, H. L. (2012).
Enterohemorrhagic and enteropathogenic Escherichia coli evolved different
strategies to resist antimicrobial peptides.GutMicrob. 3, 556–561. doi: 10.4161/
gmic.21656
Thwaite, J. E., Hibbs, S., Titball, R. W., and Atkins, T. P. (2006). Proteolytic
degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may
contribute to virulence. Antimicrob. Agents Chemother. 50, 2316–2322. doi:
10.1128/AAC.01488-05
Valvano, M. A., Messner, P., and Kosma, P. (2002). Novel pathways for
biosynthesis of nucleotide-activated glycero-manno-heptose precursors of
bacterial glycoproteins and cell surface polysaccharides. Microbiology 148,
1979–1989. doi: 10.1099/00221287-148-7-1979
Vandamme, D., Landuyt, B., Luyten, W., and Schoofs, L. (2012). A comprehensive
summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol.
280, 22–35. doi: 10.1016/j.cellimm.2012.11.009
Venturini, C., Beatson, S. A., Djordjevic, S. P., and Walker, M. J. (2010).
Multiple antibiotic resistance gene recruitment onto the enterohemorrhagic
Escherichia coli virulence plasmid. FASEB J. 24, 1160–1166. doi: 10.1096/fj.09-
144972
Walsh, C. T., and Wencewicz, T. A. (2014). Prospects for new antibiotics: a
molecule-centered perspective. J. Antibiot. 67, 7–22. doi: 10.1038/ja.2013.49
Wang, C. Y., Wang, S. W., Huang, W. C., Kim, K. S., Chang, N. S., Wang, Y. H.,
et al. (2012). Prc contributes to Escherichia coli evasion of classical complement-
mediated serum killing. Infect. Immun. 80, 3399–3409. doi: 10.1128/IAI.
00321-12
Wang, G. (2014). Human antimicrobial peptides and proteins. Pharmaceuticals
(Basel) 7, 545–594. doi: 10.3390/ph7050545
Wang, J., Ma, W., Wang, Z., Li, Y., and Wang, X. (2014). Construction and
characterization of an Escherichia coli mutant producing Kdo2-Lipid A. Mar.
Drugs 12, 1495–1511. doi: 10.3390/md12031495
Wiegand, I., Hilpert, K., and Hancock, R. E. (2008). Agar and broth dilution
methods to determine the minimal inhibitory concentration (MIC) of
antimicrobial substances. Nat. Protoc. 3, 163–175. doi: 10.1038/nprot.2007.521
Yan, J. X., Wait, R., Berkelman, T., Harry, R. A., Westbrook, J. A., Wheeler,
C. H., et al. (2000). A modified silver staining protocol for visualization
of proteins compatible with matrix-assisted laser desorption/ionization and
electrospray ionization- mass spectrometry. Electrophoresis 21, 3666–3672. doi:
10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6
Youn, M., Lee, K. M., Kim, S. H., Lim, J., Yoon, J. W., and Park, S. (2013).
Escherichia coli O157:H7 LPS O-side chains and pO157 are required for killing
Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 436, 388–393. doi:
10.1016/j.bbrc.2013.05.111
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Kuo, Chen, Chiu, Teng, Hsu, Lu, Syu, Wang, Chou and Chen.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 14 August 2016 | Volume 6 | Article 82
